Capsaicin (Standard)

• Description:

  Capsaicin (Standard) is the analytical standard of Capsaicin. This product is intended for research and analytical applications. Capsaicin ((E) -Capsaicin), an active component of chili peppers, is a TRPV1 agonist. Capsaicin has pain relief, antioxidant, anti-inflammatory and anti-cancer effects[1][2].

• Product Name Alternative:

  (E) -Capsaicin (Standard)

• UNSPSC:

  12352005

• Hazard Statement:

  H300, H315, H317, H318, H334, H335

• Target:

  Apoptosis; Autophagy; Endogenous Metabolite; Reference Standards; TRP Channel

• Type:

  Reference Standards

• Related Pathways:

  Apoptosis; Autophagy; Membrane Transporter/Ion Channel; Metabolic Enzyme/Protease; Neuronal Signaling; Others

• Applications:

  Cancer-programmed cell death

• Field of Research:

  Cancer

• Assay Protocol:

  https://www.medchemexpress.com/capsaicin-standard.html

• Purity:

  99.38

• Smiles:

  CC(C)/C=C/CCCCC(NCC1=CC=C(O)C(OC)=C1)=O

• Molecular Formula:

  C18H27NO3

• Molecular Weight:

  305.41

• Precautions:

  H300, H315, H317, H318, H334, H335

• Shipping Conditions:

  Room Temperature

• Storage Conditions:

  4°C, sealed storage, away from light and moisture

• Scientific Category:

  Reference Standards

• Clinical Information:

  Launched

• Citation 01:

  Neurosci Bull. 2025 Oct 30.|ACS Omega. 2025 Aug 21;10 (34) :39192-39202.|Acta Pharmacol Sin. 2023 Apr;44 (4) :766-779.|Acta Pharmacol Sin. 2024 Jun;45 (6) :1160-1174.|Adv Mater. 2022 Mar;34 (11) :e2108435.|Adv Sci (Weinh) . 2025 Sep 15:e10102.|Am J Pathol. 2023 May;193 (5) :548-557.|Antioxidants (Basel) . 2022 May 20;11 (5) :1003.|bioRxiv. 2024 Jan 7.|BMC Med. 2024 Nov 4;22 (1) :504.|Brain Res Bull. 2024 Jun 1:211:110950.|Cancer Cell Int. 2024 Aug 28;24 (1) :300.|Cancer Cell Int. 2025 Oct 3;25 (1) :328.|Cell Biol Int. 2024 May 5.|Cell Discov. 2024 Nov 12;10 (1) :114.|Cell Metab. 2022 Dec 6;34 (12) :1999-2017.e10.|Cell Rep. 2023 Dec 2;42 (12) :113522.|Cell. 2024 Jun 6;187 (12) :2935-2951.e19.|Cell. 2025 Oct 24:S0092-8674 (25) 01129-8.|ChemMedChem. 2025 Jan 23:e202400913.|Cytotechnology. 2025 Aug;77 (4) :141.|EMBO J. 2025 Aug;44 (15) :4222-4251.|Eur J Pharmacol. 2024 Aug 16:176909.|Exp Cell Res. 2023 Dec 15;433 (2) :113856.|Exp Ther Med. 2023 May 15;26 (1) :318.|FASEB J. 2024 May 31;38 (10) :e23661.|FASEB J. 2025 Jul 15;39 (13) :e70778.|FASEB J. 2025 May 31;39 (10) :e70657.|Front Oncol. 2022 Mar 25;12:773654.|Front Pharmacol. 2025 Sep 29:16:1671461.|Inflammopharmacology. 2025 Jan;33 (1) :257-267.|Int Immunopharmacol. 2025 May 13:158:114807.|Int J Nanomedicine. 2024 Jan 3:19:73-90.|Invest Ophthalmol Vis Sci. 2025 Jun 2;66 (6) :28.|J Biol Chem. 2022 May;298 (5) :101847.|J Cardiovasc Pharmacol. 2022 Sep 1;80 (3) :430-441.|J Cardiovasc Transl Res. 2024 Dec;17 (6) :1415-1426.|J Funct Foods. 2023 Nov , 110, 105823.|J Inflamm Res. 2024 Apr 11:17:2245-2256.|J Inflamm Res. 2024 Jan 9:17:153-170.|J Inflamm Res. 2024 Jul 2:17:4257-4275.|J Med Chem. 2025 Nov 27;68 (22) :24011-24023.|J Mol Neurosci. 2024 Aug 20;74 (3) :79.|J Mol Neurosci. 2025 Oct 14;75 (4) :138.|J Neurochem. 2025 Jan;169 (1) :e16281.|J Neurosci. 2024 Jul 17:e0740242024.|J Periodontal Res. 2024 Aug;59 (4) :798-811.|J Vis Exp. 2025 Oct 3: (224) .|Microbiol Spectr. 2022 Dec 21;10 (6) :e0241022.|Mol Med Rep. 2024 Jul;30 (1) :110.|Mol Med Rep. 2025 Dec;32 (6) :322.|Mol Med. 2024 Sep 12;30 (1) :148.|Nat Commun. 2023 Apr 17;14 (1) :2182.|Neurotherapeutics.2024 May 21:e00377.|Ocul Surf. 2024 Oct:34:406-414.|Open Biol. 2025 Mar;15 (3) :240226.|Patent. US20250127769A1.|Pathol Res Pract. 2025 Sep:273:156143.|Pharmaceuticals (Basel) . 2024 Dec 15;17 (12) :1694.|Phytomedicine. 2022 Mar 21;100:154067.|Phytomedicine. 2025 Oct:146:157130.|Phytother Res. 2022 Feb;36 (2) :938-950.|Phytother Res. 2024 Sep;38 (9) :4386-4405.|Res Sq. 2024 Sep 22.|Res Sq. 2025 Oct 8.|Research Square Preprint. 2023 Oct 13.|Research Square Preprint. 2024 Sep 03.|Research Square Print. 2022 Jun.|SSRN. 2023 Sep 11.|Tissue Cell. 2025 Nov 21:99:103243.|Toxicol Appl Pharmacol. 2026 Jan:506:117655.

• CAS Number:

  [404-86-4]